Federal regulators announced on Thursday that the U.S. Food and Drug Administration has granted approval for a new, higher‑dose formulation of the obesity medication Wegovy, produced by Danish pharmaceutical company Novo Nordisk. The authorized dosage is 7.2 milligrams, an increase from the previously available 2.4‑milligram and 6‑milligram options, and is intended for adults with obesity or overweight conditions who have not achieved sufficient weight loss with lower doses. Clinical data submitted to the FDA indicated that the higher dose can produce greater average weight reductions and may improve the durability of weight‑loss maintenance. The approval expands the therapeutic toolkit for clinicians addressing the growing public‑health challenge of obesity, potentially lowering the risk of related diseases such as type 2 diabetes and cardiovascular events. It also signals a market shift, as insurers and healthcare providers will need to assess coverage and cost implications for the more potent formulation.
- The FDA approved a 7.2 mg dose of Wegovy, a higher‑strength version of Novo Nordisk’s obesity drug.
- The new dose aims to deliver greater weight loss and better long‑term maintenance for patients who struggled with lower doses.
- Approval is based on clinical evidence showing enhanced efficacy compared with existing 2.4 mg and 6 mg formulations.
- The decision could impact treatment guidelines, insurance coverage, and the broader fight against obesity‑related health risks.